There were 1,111 press releases posted in the last 24 hours and 448,002 in the last 365 days.

Surface Oncology to Present at 2018 UBS Global Healthcare Conference

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Chief Executive Officer Jeff Goater will present a company overview at the 2018 UBS Global Healthcare Conference in New York, NY on Monday, May 21 at 9:00 a.m. eastern time.

A live webcast of the presentation will be accessible through Surface Oncology’s Investor Relations website at A replay of the webcast will be archived on Surface Oncology's website for 30 days following the presentation.    


Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies. For more information, please visit

Media Contact:
Paul Goldsmith, Ten Bridge Communications

Investor Contact:
Jessica Fees

Primary Logo